IQVIA Holdings Inc.

- As of March 31, 2026, the company had cash and cash equivalents totaling $1.947 billion and gross debt of $15.83 billion, resulting in net debt of $13.886 billion. - The net leverage ratio stood at 3.62x trailing 12 months adjusted EBITDA. - There is no specific mention of any new or planned fundraising through debt or equity in the provided text. - The company repurchased $562 million of its shares in the first quarter, with approximately $1.2 billion of repurchase authorization remaining. - No indications or guidance about future fundraising activities through new debt or equity issuance were disclosed.

- First quarter capital expenditures were $127 million. - Free cash flow was strong at $491 million, representing 100% of adjusted net income, up 15% year-over-year. - No specific future capex guidance detailed beyond Q1. - The company is heavily investing strategically in AI capabilities across Commercial Solutions and R&D, deploying over 190 AI agents covering 50+ use cases. - Strategic collaborations have been established, such as with Duke Clinical Research Institute to advance clinical research, indicating ongoing investment in partnerships to enhance capabilities. - Repurchased $562 million of shares in Q1, showing allocation of capital towards shareholder returns. - No explicit mention of increased or planned capex beyond the stated Q1 amount and strategic AI development investments.

- Continued organic growth expected: 3% in R&D Solutions (R&DS) and 5% in Commercial Solutions, with overall enterprise growth around 4%. - Revenue guidance for full year 2026: $17.15 - $17.35 billion, implying 5.2% to 6.4% growth, 5.8% at midpoint. - Second quarter 2026 revenue projected between $4.28 - $4.34 billion, representing 6.5% to 8.0% growth year-over-year. - Strong pipeline with record backlog of $34.2 billion in R&DS and significant next 12-month revenue conversion ($8.9 billion, up high single digits). - AI integration is a growth driver, expanding client adoption with 192 deployed AI agents covering 64 use cases, boosting efficiencies and enabling new offerings. - Commercial Solutions growth fueled by increased drug launches and innovation in AI-enabled analytics and consulting services. - Large pharma clients show renewed confidence, increasing pipeline assets with plans to double molecules, leading to more trials and demand. - Market demand stabilized and improving, though growth slower than pre-pandemic cruising altitude.

- Full-year 2026 revenue guidance reaffirmed at $17.15B to $17.35B, implying 5.2%-6.4% growth (5.8% midpoint). - Adjusted EBITDA guidance reaffirmed between $3.975B and $4.025B, with 4.9%-6.3% growth (5.6% midpoint). - Adjusted diluted EPS guidance raised to $12.65-$12.95, up 6.1%-8.6%, or 7.4% at midpoint. - Q2 2026 expected revenue between $4.28B and $4.34B, 6.5%-8.0% growth. - Q2 adjusted EBITDA expected at $955M-$975M, 4.9%-7.1% growth. - Q2 adjusted diluted EPS expected at $2.98-$3.08, 6.0%-9.6% growth. - FX tailwinds and acquisition effects factored into guidance. - Confidence in margin improvement due to productivity programs despite near-term mix/headwinds. - Organic growth: approx. 3% in R&DS segment, 5% in commercial segment, indicating solid operating performance.

- Q1 2026 R&D Solutions net new bookings: $2.5 billion (double-digit YoY increase). - R&D Solutions backlog as of March 31, 2026: $34.2 billion (mid-single-digit YoY increase). - Next 12-month revenue from backlog: $8.9 billion (high single-digit YoY growth). - Book-to-bill ratio in Q1: 1.04 (despite unusually low pass-through bookings). - Qualified pipeline grew mid-single digits YoY; RFP flow grew high single digits YoY. - Commercial Solutions bookings strong, with AI-enabled offerings driving pipeline growth. - Note: Book-to-bill ratios vary quarterly and are not a reliable predictor of future growth. - Backlog represents revenue expected over the next 4-7 years, with a steady conversion rate.